Compare Adaptive Biotechnologies Corp (ADPT) vs Paychex, Inc. (PAYX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Paychex, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Paychex, Inc. trades at $106.19 (market cap $38.44B). The key difference: Paychex, Inc. is far larger — about 11.5× Adaptive Biotechnologies Corp's market cap, and Paychex, Inc. pays a 4.4% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PAYX | |
|---|---|---|
Market Cap | $3.33B | $38.44B |
Sector | Health | Industrials |
52-Week High | $22.37 | $147.99 |
52-Week Low | $10.24 | $85.57 |
Enterprise Value | $3.19B | $41.92B |
Dividend Yield | — | 4.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Paychex (PAYX) trades at $108.12, up 1.66% today, showing strong momentum with three consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward movement, though RSI suggests mild overbought conditions. Fundamentally, the company maintains robust profitability with 27% net margins and 44.8% ROE, supported by steady revenue growth and strong cash flow generation.
The outlook remains positive with analyst consensus at $110 target and continued AI-driven growth initiatives. However, elevated valuation multiples and potential macroeconomic headwinds to small business hiring present risks. The stock offers a compelling combination of growth execution and shareholder returns through dividends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
